Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Equity Average (2016 - 2025)

Historic Equity Average for Champions Oncology (CSBR) over the last 15 years, with Q4 2025 value amounting to $3.9 million.

  • Champions Oncology's Equity Average rose 212607.45% to $3.9 million in Q4 2025 from the same period last year, while for Oct 2025 it was $3.9 million, marking a year-over-year increase of 212607.45%. This contributed to the annual value of $934500.0 for FY2025, which is 3161.36% down from last year.
  • Latest data reveals that Champions Oncology reported Equity Average of $3.9 million as of Q4 2025, which was up 212607.45% from $3.7 million recorded in Q3 2025.
  • Champions Oncology's Equity Average's 5-year high stood at $9.2 million during Q2 2022, with a 5-year trough of -$2.0 million in Q2 2024.
  • Its 5-year average for Equity Average is $4.8 million, with a median of $5.2 million in 2023.
  • Per our database at Business Quant, Champions Oncology's Equity Average crashed by 13417.95% in 2024 and then skyrocketed by 212607.45% in 2025.
  • Champions Oncology's Equity Average (Quarter) stood at $7.8 million in 2021, then rose by 16.31% to $9.1 million in 2022, then crashed by 89.01% to $998000.0 in 2023, then plummeted by 82.52% to $174500.0 in 2024, then skyrocketed by 2126.07% to $3.9 million in 2025.
  • Its Equity Average stands at $3.9 million for Q4 2025, versus $3.7 million for Q3 2025 and $4.6 million for Q2 2025.